The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning.

Positron emission tomography (PET) scan, mainly using 18 F-fluoro-deoxyglucose (FDG) as a tracer, is currently widely accepted as a diagnostic tool in oncology. It may lead to a change in staging and therefore in treatment management. PET can also be used to define the target volume in radiation treatment planning and to evaluate treatment response. In this review, we focused on issues concerning the role of PET in target volume delineation, both for the primary tumour and regional lymph nodes. A literature search was performed using MEDLINE. Furthermore, the following questions were addressed: does PET allow accurate tumour delineation and does it improve the outcome of radiotherapy, in terms of reduced toxicity or a higher tumour control probability? Combined computer tomography (CT) and PET information seems to influence target volume delineation. Using (CT-) PET scan, interobserver variability is being reduced. Only few studies compared delineation based on PET with pathologic examination, showing a complex relation. Preliminary results concerning incorporation of PET information in to target volume delineation varies in different tumour sites. In the field of lung cancer, incorporation of PET seems to improve tumour coverage and spare normal tissues, which may lead to less toxicity or the possibility to escalate dose. In oesophageal cancer and in lymphoma, PET scan can be used to include PET positive lymph nodes in the target volume. In most other tumour sites not enough data are currently available to draw definitive conclusions about the role of PET in radiation treatment planning.

[1]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.

[2]  Yoshimi Anzai,et al.  FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[3]  Sasa Mutic,et al.  Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[4]  Di Yan,et al.  Defining a radiotherapy target with positron emission tomography. , 2002, International journal of radiation oncology, biology, physics.

[5]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Mortensen,et al.  Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. , 2001, The Lancet. Oncology.

[7]  M Teräs,et al.  Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. , 2000, International journal of radiation oncology, biology, physics.

[8]  David Schuster,et al.  Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. , 2005, International journal of radiation oncology, biology, physics.

[9]  A. Alavi,et al.  Clinical applications of fluorodeoxyglucose-positron emission tomography in the management of malignant melanoma , 2005, Current opinion in oncology.

[10]  N. Sadato,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  K. Forster,et al.  [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Vansteenkiste Nodules, CT-scans and PET-scans: a good partnership. , 2004, Lung cancer.

[14]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[15]  S. Bujenovic The role of positron emission tomography in radiation treatment planning. , 2004, Seminars in nuclear medicine.

[16]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[17]  Ho-Fai Wong,et al.  18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  D. Slosman,et al.  The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. , 1996, Acta oto-laryngologica.

[19]  Anne Bol,et al.  Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Karin Haustermans,et al.  Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Sasa Mutic,et al.  PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. , 2003, International journal of radiation oncology, biology, physics.

[22]  M. Hata,et al.  FDG-PET scanning after radiation can predict tumor regrowth three months later. , 2003, International journal of radiation oncology, biology, physics.

[23]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[24]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[25]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[26]  J. Thie Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  T. Turkington,et al.  Clinical applications of PET in oncology. , 2004, Radiology.

[28]  Peter A S Johnstone,et al.  FDG-PET in radiotherapy treatment planning: Pandora's box? , 2004, International journal of radiation oncology, biology, physics.

[29]  C. Pinson,et al.  Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. , 2004, Journal of hepato-biliary-pancreatic surgery.

[30]  U Oppitz,et al.  3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[32]  J. Czernin,et al.  PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Henk Kramer,et al.  Current Concepts in the Mediastinal Lymph Node Staging of Nonsmall Cell Lung Cancer , 2003, Annals of surgery.

[34]  K. Geisinger,et al.  Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? , 2002, International journal of radiation oncology, biology, physics.

[35]  J. Debatin,et al.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. , 2003, JAMA.

[36]  Philippe Lambin,et al.  Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Vincent Gregoire,et al.  Is there any future in radiotherapy planning without the use of PET: unraveling the myth... , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[38]  E Bellon,et al.  Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  W Vaalburg,et al.  The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. , 2004, Cancer treatment reviews.

[40]  P. Mikosch,et al.  Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods , 2001, European Journal of Nuclear Medicine.

[41]  A. Fischman,et al.  Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[42]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[43]  R. V. van Klaveren,et al.  Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[44]  L. Adler,et al.  Positron emission tomography of soft tissue sarcomas , 2003, Current opinion in oncology.

[45]  Joos V Lebesque,et al.  Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.

[46]  Karl Herholz,et al.  Brain Tumor Extent with [11C]-L-methionine Positron Emission Tomography: Local Comparison with Stereotactic Histopatholoy. , 2004 .

[47]  J P Logue,et al.  Clinical variability of target volume description in conformal radiotherapy planning. , 1998, International journal of radiation oncology, biology, physics.

[48]  Lei Dong,et al.  Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. , 2004, International journal of radiation oncology, biology, physics.

[49]  M. Schwaiger,et al.  Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. , 1999, Archives of otolaryngology--head & neck surgery.

[50]  S. Webb,et al.  Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  Serge Goldman,et al.  Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Berlangieri,et al.  Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck Cancer , 2002 .

[54]  Sanjiv S Gambhir,et al.  FDG-PET and beyond: molecular breast cancer imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  P. Kleihues,et al.  Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. , 1988, Journal of neurosurgery.

[57]  P. Swift Novel techniques in the delivery of radiation in pediatric oncology. , 2002, Pediatric clinics of North America.

[58]  Sasa Mutic,et al.  Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. , 2004, International journal of radiation oncology, biology, physics.

[59]  Curtis B Caldwell,et al.  The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[60]  R. Coleman,et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.

[61]  M Schwaiger,et al.  The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. , 1998, International journal of radiation oncology, biology, physics.

[62]  D. Machin,et al.  Medical Statistics: A Commonsense Approach , 1993 .

[63]  K. Yuen,et al.  A prospective study to evaluate the impact of coregistered PET/CT images on radiotherapy treatment planning for esophageal cancer , 2004 .

[64]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  M. O'Doherty,et al.  [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[66]  Otakar Belohlavek,et al.  Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making , 2003 .

[67]  David Schuster,et al.  F‐18 FDG PET‐CT fusion in radiotherapy treatment planning for head and neck cancer , 2005, Head & neck.

[68]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Flamen Positron emission tomography in gastric and esophageal cancer , 2004, Current opinion in oncology.

[70]  C. Hoh,et al.  Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. , 2000, American journal of clinical oncology.

[71]  C. Rübe,et al.  2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[72]  A. Pevsner,et al.  The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  J. Luketich,et al.  The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. , 2001, Clinical lung cancer.

[74]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[75]  Staging Hodgkin's Disease with 18-FDG PET. Comparison with CT and Surgery. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[76]  Cyrill Burger,et al.  Automated functional image-guided radiation treatment planning for rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[77]  Ludy Lutgens,et al.  Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. , 2005, International journal of radiation oncology, biology, physics.

[78]  H. Steinert,et al.  Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[79]  S U Berlangieri,et al.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. , 1998, Lung cancer.

[80]  Mithat Gonen,et al.  Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. , 2004, Radiology.

[81]  C B Caldwell,et al.  Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. , 2001, International journal of radiation oncology, biology, physics.

[82]  M N Maisey,et al.  FDG–PET. A possible prognostic factor in head and neck cancer , 2002, British Journal of Cancer.

[83]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J C Rosenwald,et al.  CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. , 2001, International journal of radiation oncology, biology, physics.

[85]  Tohru Shiga,et al.  Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. , 2002, International journal of radiation oncology, biology, physics.

[86]  D. Lee,et al.  Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer , 2002, Nuclear medicine communications.

[87]  Jean-François Daisne,et al.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.

[88]  S M Larson,et al.  Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.

[89]  M. Hudson,et al.  PET imaging in pediatric Hodgkin’s lymphoma , 2004, Pediatric Radiology.

[90]  O. Hansen,et al.  The location of recurrences in patients with non-small cell lungcancer treated with involved-field irradiation , 2000 .

[91]  Koen Van Laere,et al.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[92]  M. Hudson,et al.  Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process , 2004, Pediatric Radiology.

[93]  J. Shah,et al.  Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. , 1990, American journal of surgery.

[94]  L. Mortelmans,et al.  Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[95]  P. Grigsby,et al.  Imaging in cervical cancer , 2003, Cancer.

[96]  Marc Seltzer,et al.  Positron emission tomography in urologic oncology. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[97]  H. Minn,et al.  Prospective Analysis of Accuracy of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasonography in Staging of Adenocarcinoma of the Esophagus and the Esophagogastric Junction , 2003, Annals of Surgical Oncology.

[98]  D. Owens,et al.  Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.

[99]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[100]  R. Baum,et al.  Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. , 2000, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[101]  Sasa Mutic,et al.  Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. , 2002, International journal of radiation oncology, biology, physics.

[102]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Jeffrey D Bradley,et al.  Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  B W Corn,et al.  Variation of clinical target volume definition in three-dimensional conformal radiation therapy for prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[105]  J. Buatti,et al.  The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[106]  D. Goldstein,et al.  Functional imaging of endocrine tumors: role of positron emission tomography. , 2004, Endocrine reviews.

[107]  Sadek Nehmeh,et al.  Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? , 2005, International journal of radiation oncology, biology, physics.

[108]  Gerald J. Kutcher,et al.  The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer , 2000 .

[109]  John L. Humm,et al.  Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[110]  L. Specht,et al.  FDG-PET in the clinical management of Hodgkin lymphoma. , 2004, Critical reviews in oncology/hematology.

[111]  G. Hör,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer , 1998, European Journal of Nuclear Medicine.

[112]  S. Rafla,et al.  The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. , 2005, International journal of radiation oncology, biology, physics.

[113]  Philippe Lambin,et al.  Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. , 2005, International journal of radiation oncology, biology, physics.

[114]  Karl Herholz,et al.  Delineation of Brain Tumor Extent with [11C]l-Methionine Positron Emission Tomography , 2004, Clinical Cancer Research.

[115]  H. Groen,et al.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Cyrill Burger,et al.  Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. , 2003, International journal of radiation oncology, biology, physics.

[118]  T. Solberg,et al.  A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. , 2004, Journal of neurosurgery.

[119]  K Schnabel,et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.

[120]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[121]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[122]  M. M. Mac Manus,et al.  PET scanning in lung cancer: current status and future directions. , 2003, Seminars in surgical oncology.

[123]  N. Samman,et al.  Positron emission tomography/computed tomography true fusion imaging in clinical head and neck oncology: early experience. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[124]  John L. Humm,et al.  Use of PET to monitor the response of lung cancer to radiation treatment , 2000, European Journal of Nuclear Medicine.

[125]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[126]  P. V. van Rijk,et al.  Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. , 2000, Annals of surgery.

[127]  T. Reichert,et al.  Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. , 2003, Oral oncology.

[128]  E. Stoelben,et al.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[129]  Dwight E Heron,et al.  Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. , 2004, International journal of radiation oncology, biology, physics.

[130]  T. Yen,et al.  Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. , 2004, International journal of radiation oncology, biology, physics.

[131]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[132]  David A Mankoff,et al.  Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[133]  T. Stijnen,et al.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. , 2005, The Annals of thoracic surgery.

[134]  Dean Billheimer,et al.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[135]  G. V. von Schulthess,et al.  Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[136]  Sasa Mutic,et al.  PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. , 2002, International journal of radiation oncology, biology, physics.

[137]  B A Kall,et al.  Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. , 1987, Mayo Clinic proceedings.

[138]  B. Shulkin PET applications in pediatrics. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[139]  D. Matchar,et al.  FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.

[140]  T G Turkington,et al.  Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. , 1999, Lung cancer.

[141]  A. Alavi,et al.  PET in pediatric diseases. , 2005, Radiologic clinics of North America.

[142]  H. Steinert,et al.  Whole-Body 18F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer , 2003 .